Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study
Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice: A 7-Year Cohort Study
复制标题
DOI：
10.1370/afm.2098
复制
发表时间：
2017-07-01
影响因子：
4.4
通讯作者：
Lapeyre-Mestre, Maryse
中科院分区：
文献类型：
--
作者：
Dupouy, Julie;Palmaro, Aurore;Lapeyre-Mestre, Maryse
在法国，大多数阿片类药物使用障碍病例由私人执业的全科医生用丁丙诺啡治疗。利用法国人口的代表性样本——Echantillon Generaliste des Beneficiaires的报销数据，我们调查了713名丁丙诺啡新使用者在治疗期间和治疗结束期间的死亡率，平均（SD）随访时间为4.5（1.5）年。总体死亡率为0.63 / 100人年（95% CI, 0.40-0.85）。在多变量Cox回归模型中，与接受治疗的患者相比，未接受治疗的患者死亡风险显著增加（风险比= 29.04;95% CI, 10.04-83.99）。丁丙诺啡似乎是防止死亡的有力保护因素。
In France, most cases of opioid use disorder are treated with buprenorphine by general practitioners in private practice. Using reimbursement data of a representative sample of the French population, Echantillon Generaliste des Beneficiaires, we investigated mortality during periods when patients were in and out of treatment in a cohort of 713 new users of buprenorphine having a mean (SD) followup of 4.5 (1.5) years. The mortality rate was 0.63 per 100 person-years (95% CI, 0.40-0.85) overall. In a multivariate Cox regression model, compared with being in treatment, being out of treatment was associated with a markedly increased risk of death (hazard ratio = 29.04; 95% CI, 10.04-83.99). Buprenorphine appears to be a strong protective factor against mortality.